cytosport™ complete whey pulveris
x-power, sia - pulveris
scitec nutrition® protein delitetm pulveris dzēriena pagatavošanai
bellum, sia - pulveris dzēriena pagatavošanai
scitec nutrition protein delite pulveris
power fit, sia - pulveris
ellaone
laboratoire hra pharma - ulipristal - kontracepcija, postcoital - dzimumhormoni un dzimumsistēmas modulatori dzimumorgānu sistēmas, , avārijas kontracepcijas līdzekļi - Ārkārtas kontracepcija 120 stundu laikā (piecās dienās) no neaizsargāta dzimumakta vai kontracepcijas līdzekļa mazspējas.
parsabiv
amgen europe b.v. - etelcalcetide hydrochloride - hiperparatireoidisms, sekundārais - anti-parathyroid agents, calcium homeostasis - parsabiv ir indicēts sekundāra hiperparatireozes (shpt) ārstēšanai pieaugušiem pacientiem ar hronisku nieru slimību (ckd) hemodialīzes terapijā.
alustal suspensija injekcijām
stallergenes, france - alergēnu ekstrakts - suspensija injekcijām
ultomiris
alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
digemax (2018.) šķidrums
sia "pektaļ" - šķidrums
canacor (2018.) šķidrums, -
sia "pektaļ" - šķidrums, -
priežu čiekuri sīrupā (2018.) sīrups
mītavas Čiekurs, sia - sīrups